Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Crit Care Med. 2015 Jun;43(6):1332-4. doi: 10.1097/CCM.0000000000001029.

Authors

Brad Spellberg¹, Robert A Bonomo

Affiliation

¹ Division of Infectious Diseases, Keck School of Medicine at USC and the Los Angeles County-USC Medical Center, Los Angeles, CA Department of Medicine, Department of Pharmacology, Department of Molecular Biology and Microbiology, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Case Western Reserve University, Cleveland, OH.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Acinetobacter Infections / drug therapy*
Acinetobacter Infections / mortality*
Anti-Bacterial Agents / therapeutic use*
Carbapenems / therapeutic use*
Colistin / therapeutic use*
Female
Humans
Male
Minocycline / analogs & derivatives*

Substances

Anti-Bacterial Agents
Carbapenems
Minocycline
Colistin

Grants and funding